OLIMPIC: a 12-month study on the criteria driving retreatment with ranibizumab in patients with visual impairment due to myopic choroidal neovascularization.

Détails

ID Serval
serval:BIB_1F2AC9D787C7
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Titre
OLIMPIC: a 12-month study on the criteria driving retreatment with ranibizumab in patients with visual impairment due to myopic choroidal neovascularization.
Périodique
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
Auteur(s)
Ricci F., Staurenghi G., Varano M., Eandi C., Sinibaldi T.L., Colombo L., Bartezaghi M., Bassanini S.
ISSN
1435-702X (Electronic)
ISSN-L
0721-832X
Statut éditorial
Publié
Date de publication
04/2019
Peer-reviewed
Oui
Volume
257
Numéro
4
Pages
759-768
Langue
anglais
Notes
Publication types: Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial
Publication Status: ppublish
Résumé
To evaluate criteria driving retreatment with ranibizumab in Italian patients with myopic choroidal neovascularization (mCNV).
OLIMPIC was a 12-month, phase IIIb, open-label study. Patients with active mCNV were treated with ranibizumab 0.5 mg according to the European label. The study assessed local criteria in Italy driving retreatment decisions with ranibizumab; and the efficacy, safety, and tolerability of ranibizumab.
The mean (standard deviation [SD]) age of treated patients (N = 200) was 61.8 (12.7) years; range 22-85 years. The multivariate regression model indicated that presence of active leakage (odds ratio [OR] 95% confidence interval [CI]: 11.30 [1.03-124.14]), presence of intraretinal fluid (OR [95%CI]: 28.21 [1.55-513.73]), and an improvement in best-corrected visual acuity (BCVA) from baseline < 10 letters (OR [95%CI]: 17.60 [1.39-222.75]) were the factors with the greatest effect on retreatment with ranibizumab. The mean (SD) BCVA gain from baseline to month 12 was 8.4 (12.8) letters (P < 0.0001). The mean (SD) number of injections was 2.41 (1.53); range 1-9. Ocular and non-ocular adverse events were reported in 41 (20.5%) and 30 (15.0%) patients, respectively.
Individualized treatment with ranibizumab was effective in improving BCVA in patients with mCNV over 12 months. Both anatomical and functional variables had significant effects on causing retreatment. There were no new safety findings.
www.ClinicalTrials.Gov (NCT No: NCT02034006).
Mots-clé
Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors/therapeutic use, Choroidal Neovascularization/complications, Choroidal Neovascularization/drug therapy, Choroidal Neovascularization/physiopathology, Female, Humans, Intravitreal Injections, Male, Middle Aged, Myopia, Degenerative/drug therapy, Myopia, Degenerative/etiology, Myopia, Degenerative/physiopathology, Prospective Studies, Ranibizumab/therapeutic use, Retreatment, Subretinal Fluid, Vascular Endothelial Growth Factor A/antagonists & inhibitors, Vision Disorders/drug therapy, Vision Disorders/etiology, Vision Disorders/physiopathology, Visual Acuity/physiology, Young Adult, Choroidal neovascularization, Pathologic myopia, Ranibizumab, Retreatment criteria, Visual acuity, Visual impairment
Pubmed
Web of science
Open Access
Oui
Création de la notice
12/03/2021 19:27
Dernière modification de la notice
26/03/2021 6:35
Données d'usage